Articles

ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype

Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan;Department of Pediatrics, St. Luke’s International Hospital, Chuo-ku, Tokyo, Japan
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan
Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan
Division of Genetics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan
Laboratory for Genotyping Development, Center for Integrative Medical Sciences (IMS), RIKEN, Yokohama-shi, Kanagawa, Japan
Department of Systems BioMedicine, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan;Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan;Department of Hematology/Oncology, Tokyo Metropolitan Children’s Medical Center, Fuchu-shi, Tokyo, Japan
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan;Division of Pediatric Hematology and Oncology, Ibaraki Children’s Hospital, Mito-shi, Ibaraki, Japan
Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan
Division of Genetics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan;Division of Stem Cell Transplant and Cellular Therapy, Children’s Cancer Center, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan
Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
Department of Pediatrics, Chiba University Graduate School of Medicine, Chiba-shi, Chiba, Japan
Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan
Department of Haematology/Oncology, Chiba Children’s Hospital, Chiba-shi, Chiba, Japan
Department of Pediatrics, Dokkyo Medical University, Mibu, Tochigi, Japan
Division of Pediatric Hematology and Oncology, Ibaraki Children’s Hospital, Mito-shi, Ibaraki, Japan
Department of Pediatrics, Yokohama City University Hospital, Yokohama-shi, Kanagawa, Japan
Department of Pediatrics, Saitama Medical Center, Saitama Medical University, Kawagoe-shi, Saitama, Japan
Department of Pediatrics, Tokai University School of Medicine, Isehara-shi, Kanagawa, Japan
Department of Pediatrics, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan
Department of Pediatrics, Japanese Red Cross Narita Hospital, Narita-shi, Chiba, Japan
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan;Division of Leukemia and Lymphoma, Children’s Cancer Center, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan
Department of Hematology/Oncology, Nagano Children’s Hospital, Azumino-shi, Nagano, Japan
Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan
Department of Hematology/Oncology, Tokyo Metropolitan Children’s Medical Center, Fuchu-shi, Tokyo, Japan
Laboratory of Clinical Sequence, Department of Computational biology and medical Sciences, Graduate school of Frontier Sciences, The University of Tokyo, Minato-ku, Tokyo, Japan
Division of Genetics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan
Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan
Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan
Laboratory for Genotyping Development, Center for Integrative Medical Sciences (IMS), RIKEN, Yokohama-shi, Kanagawa, Japan
National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan
Department of Child Health, Faculty of Medicine, University of Tsukuba, Tsukuba-shi, Ibaraki, Japan
Department of Hematology/Oncology, Saitama Children’s Medical Center, Saitama-shi, Saitama, Japan
Department of Pediatrics, St. Luke’s International Hospital, Chuo-ku, Tokyo, Japan
Department of Pediatrics, Toho University Omori Medical Center, Ohta-ku, Tokyo, Japan
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan
Vol. 102 No. 1 (2017): January, 2017 https://doi.org/10.3324/haematol.2016.151035